Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system

Abstract

ROCCadherin-17, also called liver-intestine cadherin, is a calcium-dependent transmembrane glycoprotein that mediates cell-cell adhesion in intestinal epithelium. Expression of cadherin-17 was reported in gastric, pancreatic, and colorectal adenocarcinomas but not in other tumors. Whether cadherin-17 can be used as a marker for diagnosis of cancers is still unclear. In this study, we used immunohistochemical methods to stain cadherin-17 in tissue arrays containing most normal tissues and 518 carcinomas from many anatomic sites. Among normal tissues, the expression of cadherin-17 was limited to epithelial cells of small intestine and colon. Colorectal adenocarcinomas showed staining in 96% of cases and most of them had strong and diffuse staining. Gastric, pancreatic, and biliary adenocarcinomas showed diffuse or scattered staining in about 25-50% of cases. Fewer than 1% of carcinomas outside the digestive system were positive for cadherin-17. When a two-marker, Cadherin-17/cytokeratin 7, profile was used, 37 of 38 (97%) cadherin-17( þ )/cytokeratin 7(À) tumors were colorectal adenocarcinomas; 49 of 56 (86%) cadherin-17( þ )/cytokeratin 7( þ ) tumors were gastric, pancreatic, or biliary adenocarcinomas. Our results show that cadherin-17 is a useful immunohistochemical marker for diagnosis of adenocarcinomas of the digestive system.

Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers

“…Of 331 tumors including 44 breast cancers, 39 uterine cervical carcinomas, 50 lung cancers, 47 renal cell carcinomas, 89 ovarian cancers, and 39 prostatic cancers; cadherin-17 was expressed in only one (0.3%) prostatic adenocarcinoma. 12 These results support the utility of cadherin-17 as a useful diagnostic marker of gastrointestinal adenocarcinoma. Park et al 21 similarly found a high concordance between the staining reactions in primary and metastatic colorectal carcinomas.…”

“…3,7,19,20 Cadherin-17, also called liverintestinal cadherin or human peptide transporter-1, is a sensitive and specific marker for adenocarcinomas of the digestive system, especially colorectal adenocarcinomas. [11][12][13][14][15] In the study of Su et al, 12 expression of cadherin-17 was very common in colorectal adenocarcinomas (96%) and evident in more than half of gastric and pancreatic adenocarcinomas. In contrast, cadherin-17 expression was very uncommon in carcinomas arising outside the gastrointestinal tract.…”

“…Cadherin-17 (CDH17), also called liver-intestinal cadherin or human peptide transporter-1, has been recently recognized as a sensitive and specific marker for adenocarcinoma of the digestive system, especially colorectal adenocarcinoma. [11][12][13][14][15] Conversely, GATA3, a transcription factor, is a newly described marker of urothelial carcinoma. [16][17][18] However, the expression of cadherin-17 and GATA3 in primary adenocarcinoma of the urinary bladder has not been well characterized.…”

An RGD Motif Present in Cadherin 17 Induces Integrin Activation and Tumor Growth

“…Cells-CDH17 overexpression has been reported in some pancreatic tumors (3). Here, in a sample set of 48 patients with pancreatic cancer, we detected CDH17 expression in 60.4% of tumors by immunohistochemistry.…”

Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas

“…11,48 A few studies have demonstrated the clinical utility of CDH17 as an immunomarker of GI adenocarcinomas. 11,[48][49][50] CDH17 is highly sensitive for primary and metastatic CRCs and is positive in up to 96% to 99% of examined cases. However, CDH17 positivity is also seen at a high frequency in adenocarcinomas of the esophagus (67%-82%), stomach (25%-90%), pancreas (18%-52%), and bile duct (27%-53%).…”